Trial reportPharmacoEconomics2018
Impact of Adverse Events on Health Utility and Health-Related Quality of Life in Patients Receiving First-Line Chemotherapy for Metastatic Breast Cancer: Results from the SELECT BC Study.
Trial report in PharmacoEconomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Pooled it
- Association of adverse events and quality of life in patients with unresectable hepatocellular carcinoma.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Trial
- Cost-Effectiveness Analysis ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia.Clinical drug investigation · 2025Article
- Cost-effectiveness analysis model for sotagliflozin compared with insulin monotherapy for patients with type 1 diabetes and chronic kidney disease.Journal of managed care & specialty pharmacy · 2025Article
- Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure.Journal of comparative effectiveness research · 2024Article
- Foot Health in People with Cancer Undergoing Chemotherapy: A Scoping Review.Healthcare (Basel, Switzerland) · 2023Article
- Randomized clinical trial quantifying the effectiveness of a self-monitoring intervention in cancer patients with peripheral neuropathy: A quantitative study.Asia-Pacific journal of oncology nursing · 2023Article
- Quality of life of patients with hematological malignancies and factors affecting health state utility values.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States.Journal of managed care & specialty pharmacy · 2022Article
- Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy.Journal of pharmaceutical health care and sciences · 2022Article
- Observational
- Changes in Health State Utility Values in Japanese Patients with End-Stage Breast Cancer.Current oncology (Toronto, Ont.) · 2021Article
- Cost-Effectiveness Analysis of Local Treatment in Oligometastatic Disease.Frontiers in oncology · 2021Article
- Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Assessing health-related quality of life in cancer survivors: factors impacting on EORTC QLU-C10D-derived utility values.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020Article
- The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa.Health and quality of life outcomes · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to investigate the impact of adverse events (AEs) on health utility and health-related quality of life (HRQOL) in patients with metastatic breast cancer undergoing first-line chemotherapy.
methodsWe analyzed the data from the SELECT BC study, a multicenter, open-label, randomized, phase III study conducted in Japan, which compared first-line S-1 with taxane therapies. Heath utility and HRQOL were assessed using the EQ-5D-3L and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) at baseline and 3, 6, and 12 months after treatment initiation. Health utility was calculated based on societal preferences, and AEs were reported at each cycle of the study treatment. Linear marginal mean models were used to quantify the impact of the last AEs (with 10 or more incidences) observed before HRQOL assessment on health utility and HRQOL.
resultsAnalysis included 380 patients and 12 (of 15) AEs. Grade 1 nausea and oral mucositis, grade 1 and 2 edema, and grade 2 fatigue, motor and sensory neuropathy, and myalgia were significantly associated with disutility, measured using the EQ-5D-3L. Grade 1 oral mucositis, grade 1 and 2 fatigue, and grade 2 sensory neuropathy were significantly associated with impaired global health status in the EORTC QLQ-C30. AEs associated with decrements in the five functioning scales included fatigue, oral mucositis, nausea, edema, motor and sensory neuropathy, and myalgia.
conclusionsWe reported disutilities caused by AEs in patients with metastatic breast cancer under chemotherapy. These findings can be applied to future model-based cost-effectiveness analyses. TRIAL REGISTRATION NUMBER: C000000416.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.